{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:08:06Z","timestamp":1792033686722,"version":"4.4.0"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec id=\"ab-eoi250041-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The use of systemic mammalian target of rapamycin (mTOR) inhibitor (MTI) therapy may confer benefits against the development of proliferative vitreoretinopathy (PVR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250041-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine the use of systemic MTI therapy for the prevention of PVR among patients who underwent initial retinal detachment (RD) repair.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250041-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a retrospective cohort study aggregating deidentified electronic health record data from January 2003 to January 2025, from 15 countries. The study included 681 patients who underwent primary RD repair while receiving systemic MTI therapy at least 3 months before and 1 year after initial RD repair. This cohort was compared with a control group of 47\u202f626 patients never exposed to systemic mTOR inhibition. After propensity score matching, outcomes from 681 patients in each cohort were analyzed after 1 year following their initial RD surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250041-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Patients were stratified by use of systemic mTOR therapy or not using RxNorm code.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250041-8\">\n                    <jats:title>Main Outcome and Measures<\/jats:title>\n                    <jats:p>Relative risk (RR) of developing a PVR-related RD and requiring a subsequent ocular intervention including pars plana vitrectomy (PPV), and complex RD repair within 6 months and 1 year of follow-up. Patients who underwent initial RD repair while receiving systemic MTI therapy were separately compared with a matched cohort of patients with concomitant use of systemic methotrexate (MTX) for the same measures at 6 months and 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250041-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 681 and 47\u202f626 patients who underwent initial RD repair with concomitant use of an MTI or not, respectively, were identified prior to PSM. The mean (SD) age in the MTI cohort was 66.5 (15.4) years; 319 (46.8%) were female and 319 (46.8%) were male. In the control cohort, the mean (SD) age was 64.5 (17.6) years; 16\u202f140 (33.9%) were female and 27\u202f858 (58.5%) were male. At 1 year, concomitant use of systemic MTI therapy was associated with a decreased risk of developing a subsequent RD (RR, 0.58; 95% CI, 0.36-0.94;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.03) compared with matched patients who underwent initial RD repair without exposure to systemic MTI therapy. Moreover, concomitant use of systemic MTI therapy was associated with a decreased risk of requiring subsequent PPV (RR, 0.57; 95% CI, 0.40-0.82;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and complex RD repair (RR, 0.60; 95% CI, 0.40-0.91;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.01) when compared with matched patients who underwent initial RD repair without exposure to systemic MTI therapy at 1 year. There was no difference in the development of subsequent RD and need for PPV or complex RD repair when comparing patients who underwent initial RD repair with concomitant systemic MTI therapy to a matched cohort of patients with concomitant use of systemic MTX therapy at 6 months and 1 year.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250041-10\">\n                    <jats:title>Conclusion and Relevance<\/jats:title>\n                    <jats:p>Patients who underwent initial RD repair and were concomitantly being treated with systemic MTI therapy were less likely to develop a subsequent PVR-related RD compared with matched patients not exposed to systemic MTI therapy. Future studies are needed to investigate MTI therapy safety and efficacy profile in this setting of potential PVR prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2025.2497","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:31:11Z","timestamp":1754580671000},"page":"777","source":"Crossref","is-referenced-by-count":5,"title":["Mammalian Target Rapamycin Inhibition as a Therapeutic Target for Prevention of Proliferative Vitreoretinopathy"],"prefix":"10.1001","volume":"143","author":[{"given":"Amer F.","family":"Alsoudi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Loya","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Wai","sequence":"additional","affiliation":[{"name":"Horngren Family Vitreoretinal Center, Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euna","family":"Koo","sequence":"additional","affiliation":[{"name":"Horngren Family Vitreoretinal Center, Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Y.","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[{"name":"Horngren Family Vitreoretinal Center, Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Rahimy","sequence":"additional","affiliation":[{"name":"Horngren Family Vitreoretinal Center, Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California"},{"name":"Department of Ophthalmology, Palo Alto Medical Foundation, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"eoi250041r1","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/S0161-6420(97)30167-5","article-title":"Post-traumatic proliferative vitreoretinopathy. the epidemiologic profile, onset, risk factors, and visual outcome.","volume":"104","author":"Cardillo","year":"1997","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi250041r2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0002-9394(98)00115-9","article-title":"Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial.","volume":"126","author":"Wiedemann","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"eoi250041r3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4103\/2008-322X.188390","article-title":"Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: a randomized pilot study.","volume":"11","author":"Tousi","year":"2016","journal-title":"J Ophthalmic Vis Res"},{"issue":"4","key":"eoi250041r4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1080\/08820538.2021.1890791","article-title":"Molecular targets for proliferative vitreoretinopathy.","volume":"36","author":"Wu","year":"2021","journal-title":"Semin Ophthalmol"},{"issue":"7","key":"eoi250041r5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00417-008-0829-0","article-title":"One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy.","volume":"246","author":"Yamakiri","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"eoi250041r6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/archopht.125.9.1161","article-title":"Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy.","volume":"125","author":"Schiff","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"eoi250041r7","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.ophtha.2008.05.016","article-title":"Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial.","volume":"115","author":"Ahmadieh","year":"2008","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi250041r8","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.ajpath.2013.01.052","article-title":"Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.","volume":"182","author":"Pennock","year":"2013","journal-title":"Am J Pathol"},{"issue":"3","key":"eoi250041r9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0161-6420(95)31007-X","article-title":"The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy.","volume":"102","author":"Fekrat","year":"1995","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi250041r10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.01.021","article-title":"Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial.","volume":"124","author":"Banerjee","year":"2017","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi250041r11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ophtha.2006.08.042","article-title":"Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy.","volume":"114","author":"Wickham","year":"2007","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi250041r12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/BF00184007","article-title":"Radiation therapy in proliferative vitreoretinopathy. a prospective randomized study.","volume":"232","author":"Binder","year":"1994","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"eoi250041r13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3928\/1542-8877-19890401-10","article-title":"Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? a controlled study in humans.","volume":"20","author":"Berman","year":"1989","journal-title":"Ophthalmic Surg"},{"issue":"5","key":"eoi250041r14","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/S0008-4182(05)80052-3","article-title":"Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy.","volume":"40","author":"Munir","year":"2005","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"eoi250041r15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/IAE.0000000000001584","article-title":"Efficacy of intravitreal injection of bevacizumab in vitrectomy for patients with proliferative vitreoretinopathy retinal detachment: a meta-analysis of prospective studies.","volume":"38","author":"Zhao","year":"2018","journal-title":"Retina"},{"issue":"7","key":"eoi250041r16","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0161-6420(01)00589-9","article-title":"Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial.","volume":"108","author":"Asaria","year":"2001","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi250041r17","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.ophtha.2004.05.036","article-title":"A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy.","volume":"111","author":"Charteris","year":"2004","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi250041r18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0161-6420(84)34318-4","article-title":"5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite.","volume":"91","author":"Blumenkranz","year":"1984","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi250041r19","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.ophtha.2024.01.032","article-title":"Association of cutaneous keloids, hypertrophic scarring, and fibrosis with risk of postoperative proliferative vitreoretinopathy.","volume":"131","author":"Mammo","year":"2024","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi250041r22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jdermsci.2019.06.008","article-title":"Topical delivery of mTOR inhibitor halts scarring.","volume":"95","author":"Webber","year":"2019","journal-title":"J Dermatol Sci"},{"issue":"5","key":"eoi250041r23","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2008-02-137141","article-title":"mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.","volume":"112","author":"Teachey","year":"2008","journal-title":"Blood"},{"issue":"1","key":"eoi250041r24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/IIO.0000000000000258","article-title":"Proliferative vitreoretinopathy: a review.","volume":"59","author":"Idrees","year":"2019","journal-title":"Int Ophthalmol Clin"},{"issue":"9","key":"eoi250041r25","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1128\/MCB.01321-10","article-title":"Pathological signaling via platelet-derived growth factor receptor alpha involves chronic activation of Akt and suppression of p53.","volume":"31","author":"Lei","year":"2011","journal-title":"Mol Cell Biol"},{"issue":"11","key":"eoi250041r26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028068","article-title":"Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression.","volume":"6","author":"Jung","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"eoi250041r27","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41419-024-07077-8","article-title":"Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research.","volume":"15","author":"Son","year":"2024","journal-title":"Cell Death Dis"},{"issue":"5","key":"eoi250041r28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12094-013-1109-y","article-title":"Efficacy of rapamycin against glioblastoma cancer stem cells.","volume":"16","author":"Mendiburu-Eli\u00e7abe","year":"2014","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"eoi250041r29","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.18632\/oncotarget.1310","article-title":"Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.","volume":"4","author":"Francipane","year":"2013","journal-title":"Oncotarget"},{"issue":"1","key":"eoi250041r30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1245\/s10434-013-3146-8","article-title":"Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.","volume":"21","author":"Cai","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"eoi250041r31","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s10495-015-1158-5","article-title":"Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells.","volume":"20","author":"Soo","year":"2015","journal-title":"Apoptosis"},{"issue":"6","key":"eoi250041r32","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"eoi250041r33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13058-021-01394-y","article-title":"Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.","volume":"23","author":"Rozenblit","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"4","key":"eoi250041r34","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jaapos.2017.04.012","article-title":"Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex.","volume":"21","author":"Nallasamy","year":"2017","journal-title":"J AAPOS"},{"key":"eoi250041r35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ajo.2017.11.025","article-title":"Personalized proteomics in proliferative vitreoretinopathy implicate hematopoietic cell recruitment and mTOR as a therapeutic target.","volume":"186","author":"Roybal","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"eoi250041r36","first-page":"675","article-title":"PI3K\/AKT\/mTOR signaling pathway inhibitors in proliferation of retinal pigment epithelial cells.","volume":"5","author":"Cai","year":"2012","journal-title":"Int J Ophthalmol"},{"issue":"8","key":"eoi250041r37","first-page":"594","article-title":"mTOR and Rho family of GTPases regulate epithelial phenotype in injured retinal pigment epithelium.","volume":"58","author":"Chang","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"eoi250041r38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/iovs.65.11.1","article-title":"Knockdown of HSPA13 inhibits TGF\u00df1-induced epithelial-mesenchymal transition of RPE by suppressing the PI3K\/Akt signaling pathway.","volume":"65","author":"Gao","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"eoi250041r39","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1167\/iovs.09-3445","article-title":"Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the AKT\/mTOR pathway.","volume":"50","author":"Lewis","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"eoi250041r40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors.","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant Rev (Orlando)"},{"issue":"13","key":"eoi250041r41","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy.","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"eoi250041r42","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1167\/iovs.14-15997","article-title":"Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin.","volume":"56","author":"Nieto","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"eoi250041r43","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2147\/OPTH.S27896","article-title":"Proliferative vitreoretinopathy: current and emerging treatments.","volume":"6","author":"Sadaka","year":"2012","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"eoi250041r44","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/eye.2014.21","article-title":"Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy.","volume":"28","author":"Ghasemi Falavarjani","year":"2014","journal-title":"Eye (Lond)"},{"issue":"5","key":"eoi250041r45","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1046\/j.1442-9071.2002.00554.x","article-title":"Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery.","volume":"30","author":"Kumar","year":"2002","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"eoi250041r46","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1167\/iovs.15-16526","article-title":"A novel approach of daunorubicin application on formation of proliferative retinopathy using a porous silicon controlled delivery system: pharmacodynamics.","volume":"56","author":"Hou","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"eoi250041r47","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.ophtha.2022.05.024","article-title":"Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial.","volume":"129","author":"Schaub","year":"2022","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi250041r48","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ajo.2008.05.002","article-title":"Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy.","volume":"146","author":"Chang","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"eoi250041r49","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1177\/1120672120976038","article-title":"Intraocular mitomycin C use in the treatment and prophylaxis of proliferative vitreoretinopathy in severe traumatic retinal detachments.","volume":"31","author":"G\u00fcrelik","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"10","key":"eoi250041r50","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1097\/IAE.0000000000004182","article-title":"Oral curcumin to reduce risk of proliferative vitreoretinopathy following rhegmatogenous retinal detachment repair.","volume":"44","author":"Zheng","year":"2024","journal-title":"Retina"},{"issue":"7","key":"eoi250041r51","first-page":"6060","article-title":"Rho-kinase pathway inhibition for proliferative vitreoretinopathy: assessing the therapeutic potential of netarsudil.","volume":"65","author":"Sanchez-Suarez","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"eoi250041r52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000500271","article-title":"Repeated injection of methotrexate into silicone oil-filled eyes for grade C proliferative vitreoretinopathy: a pilot study.","volume":"242","author":"Nourinia","year":"2019","journal-title":"Ophthalmologica"},{"issue":"10","key":"eoi250041r53","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1007\/s00417-021-05206-z","article-title":"Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy.","volume":"259","author":"Roca","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"eoi250041r54","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.oret.2024.05.016","article-title":"Intravitreal infliximab for the treatment of proliferative vitreoretinopathy (FIXER): a randomized controlled phase ii trial.","volume":"8","author":"Younes","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"eoi250041r20","unstructured":"Aldeyra Therapeutics. The GUARD trial\u2014part 1: a phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for prevention of proliferaivie vitreoretinopathy. Accessed November 10, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04136366"},{"key":"eoi250041r21","unstructured":"Aldeyra Therapeutics. Top-line results from part 1 of the phase 3 GUARD trial of ADX-2191 in proliferative vitreoretinopathy. Accessed July 2, 2025. https:\/\/ir.aldeyra.com\/static-files\/cde1aa20-d22a-4f38-a9a5-523b803aca40"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2837246\/jamaophthalmology_alsoudi_2025_oi_250041_1758049766.74853.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T15:19:51Z","timestamp":1758208791000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2837246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.2497","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}